Revolution Medicines (RVMD) financial statements
Revolution Medicines reported revenue of $0 in fiscal 2025, down 10.5% a year over 5 years.
Net income was -$1.1B.
Free cash flow was -$914M.
The diluted share count rose 8171% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Revolution Medicines's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20M | $50M | $43M | $29M | $35M | $12M | $0 | $0 |
| Research and development | $51M | $92M | $132M | $187M | $253M | $423M | $592M | $987M |
| Selling, general and admin | $9M | $12M | $21M | $30M | $41M | $76M | $97M | $195M |
| Operating income | -$40M | -$54M | -$111M | -$188M | -$258M | -$487M | -$690M | -$1.2B |
| Interest expense | $116,000 | $106,000 | $71,000 | $12,000 | $0 | $0 | $0 | $24M |
| Pre-tax income | -$42M | -$52M | -$109M | -$187M | -$249M | -$440M | -$601M | -$1.1B |
| Income tax | — | -$4M | -$371,000 | $0 | -$420,000 | -$4M | -$753,000 | $0 |
| Net income | -$42M | -$48M | -$108M | -$187M | -$249M | -$436M | -$600M | -$1.1B |
| EPS (diluted) | -$21.24 | -$22.33 | -$2.01 | -$2.57 | -$3.08 | -$3.86 | -$3.58 | -$5.95 |
| Diluted shares | 2M | 3M | 55M | 73M | 81M | 113M | 168M | 190M |
| Operating margin | -200.0% | -108.2% | -257.5% | -639.7% | -730.0% | -4207.1% | — | — |
| Net margin | -207.2% | -95.2% | -251.6% | -636.6% | -703.0% | -3768.3% | — | — |
Balance sheet
Fiscal years, from Revolution Medicines's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $70M | $123M | $441M | $577M | $645M | $1.9B | $2.3B | $2.0B |
| Total current assets | — | $134M | $454M | $590M | $660M | $1.9B | $2.3B | $2.1B |
| Property, plant and equipment | — | $7M | $9M | $12M | $19M | $23M | $24M | $33M |
| Goodwill | — | $15M | $15M | $15M | $15M | $15M | $15M | $15M |
| Total assets | — | $221M | $567M | $738M | $812M | $2.1B | $2.6B | $2.4B |
| Total current liabilities | — | $43M | $47M | $60M | $62M | $144M | $164M | $290M |
| Total liabilities | — | $68M | $93M | $135M | $127M | $236M | $293M | $723M |
| Shareholders' equity | -$108M | -$153M | $475M | $603M | $685M | $1.8B | $2.3B | $1.6B |
| Net debt | -$70M | -$17M | -$104M | -$108M | -$161M | -$696M | -$543M | -$384M |
Cash flow
Fiscal years, from Revolution Medicines's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1M | -$50M | -$100M | -$147M | -$224M | -$351M | -$557M | -$898M |
| Capital spending | $1M | $3M | $3M | $7M | $11M | $8M | $10M | $16M |
| Free cash flow | -$286,000 | -$52M | -$103M | -$154M | -$235M | -$358M | -$568M | -$914M |
| Stock-based compensation | $855,000 | $3M | $9M | $21M | $31M | $62M | $79M | $118M |
| Dividends paid | — | — | $0 | — | — | — | — | — |
| Free cash flow margin | -1.4% | -104.3% | -239.6% | -523.0% | -664.8% | -3094.1% | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RVMD.
Open RVMD in InvestinglyQuestions
What was Revolution Medicines's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
How much free cash flow does Revolution Medicines generate?
-$914M in fiscal 2025 (operating cash flow minus capital spending).
From Revolution Medicines's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.